Indeed, our new monoclonal antibody against EphA5 (11C12), when administered in combination with radiotherapy, sensitized lung cancer cells to IR in vitro and improved the overall survival of mice bearing human lung cancer xenografts. Here, EPHA5 is linked to lung carcinoma.